Faculty Profile
Dr. Fanta Paul Fanta, M.D.
Assistant Clinical Professor of Medicine
Division of Hematology-Oncology
Office Address:
Division of Hematology-Oncology
University of California, San Diego
Moores UCSD Cancer Center, MC-0987
3855 Health Sciences Drive
La Jolla, CA 92093
Office:(858) 822-6185
FAX: (858) 822-6186
| Education/Training | Research Interests | Publications | Laboratory |
Education and Training
| BS | Biology/Chemistry/Math, University of Arizona | 1983 |
| MS | Microbiology/Immunology, University of Arizona | 2001 |
| MD | University of Arizona | 2001 |
| Resident | Scripps-Green Hospital, La Jolla, CA | 2001-2004 |
| Fellowship | Hematology-Oncology, Scripps Clinic, La Jolla, CA | 2004-2007 |
Research Interests
The diagnosis and management of gastrointestinal cancers has dramatically changed in the past several years. By incorporating biotechnology, bioinformatics, molecular biomarker analyses, pharmocogenomic data, in the setting of prospective clinical trials, we may better identify patients who will benefit from chemotherapy, avoid toxicities from treatment, and develop a predictive therapeutic strategy unique to a patient’s disease. Enrollment of patients with cancers of the colon, rectum, anus, stomach, esophagus, GI stromal tumors, hepatocellular carcinoma, pancreas, gall-bladder, and cholangiocarcinoma into our clinical trials is a priority.
Publications
Leong S.P.L, Xu M.J., Alberts D.S., Wang T.F, Peng Y.M. Hersh E.M., Taylor C.W. Fanta P., Salmon S.E. Chemosensitivity of human melanoma to cisplatin and heat at pharmacokinetic doses achievable by isolated hyperthermic perfusion. Regional Cancer Treatment, 4:216-219, 1992
Taylor C.W., Liu R., Fanta P., Salmon S.E. Effects of suramin on the in-invitro growth of fresh human tumors. Journal of the Natl. Cancer Inst, 84: 489-494, 1992.
Massimo F., Alberts D.S., Garcia D., Emerson J., Fanta P., Liu R., Salmon S.E. In-vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in-vitro response and clinical outcome. Gynecologic Oncology, 55: S156-S163, 1994.
Alberts D.S., Fanta P., Running K., Liu-Stevene R., Salmon S.E. In-vitro phase II comparison of a novel platinum analog, nedaplatin (254-S), to cisplatin and carboplatin against fresh human ovarian cancers. Cancer Chemotherapy and Pharmacology, 39(6): 493-497, 1997.
Monk B.J., Alterts D.S., Burger R.A., Fanta P., Hallum A.V., Salmon S.E. In-vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S) with that of cisplatin and carboplatin against fresh human cervical cancers. Gynecologic Oncology, 71:308-312, 1998.
Scott K., Fanta P., Calaluce R., Dalkin B., Weinstein R.S., Nagle R. Diagnostic frozen sextant biopsies: an approach for preserving protein and RNA for additional studies. The Prostate: 2000, 44:296-302, 2000.
Taylor C.W., Dorr R.T., Fanta P., Hersh E., Salmon S.E. A phase I and pharmacodynamic evaluation of PEG-L-Asparaginase inpatients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 47(1): 83-88, 2001.
Baur J., Fanta P., Andrey J. Hemoglobin Lepore: an unusual presentation of microcytic anemia, Proceedings of the American College of Physicians, October 14, 2005.
Fanta P., Saven A. Book chapter “Hairy cell leukemia” in Rare Hematological Malignancies, edited by Stephen M. Ansell, Spring Publishing, 2007.
